Patients treated with the Boston Scientific Vessix Renal Denervation System experienced a significant and sustained reduction in blood pressure, according to new data presented today at the Transcatheter Cardiovascular Therapeutics Conference (TCT 2013) in San Francisco. An interim analysis of 139 patients enrolled in the REDUCE-HTN post market study affirms the device safety profile and effective treatment for resistant hypertension.

Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate the use of dual anti-platelet therapy (DAPT) for a three-month duration following treatment with the company's Xience family of drug eluting stents (DES). 

Amaranth Medical, a privately held medical device company, presented positive six-month angiographic results from its first-in-human study including patients undergoing percutaneous coronary intervention (PCI) with single coronary lesions. 

medtronic corevalve cath lab hybrid or heart valve repair study TCT 2013

The CoreValve U.S. pivotal trial showed very positive results for the Medtronic CoreValve system, comparable or better than data from the Sapien Partner Trial.

Terumo Interventional Systems announced the launch of the 0.018-inch Glidewire Advantage peripheral guidewire during the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

Philips and Infraredx Inc. announced a non-exclusive resale agreement for Infraredx’s TVC imaging system. Under the terms of the agreement, Philips will sell Infraredx’s TVC imaging system alongside its Allura interventional X-ray systems in North America and Europe.

The findings of a Harvey L. Neiman Health Policy Institute study published online in the Journal of the American College of Radiology (JACR) confirm a major shift in practice at American hospitals regarding central venous procedures.

OrbusNeich announced the publication of a study demonstrating that lesion preparation with the company’s Scoreflex coronary dilatation catheter prior to drug eluting stent (DES) implantation is associated with equivalent acute stent expansion and less in-stent late loss versus a non-compliant balloon.

Nonin Medical Inc., the inventor of finger pulse oximetry and a leader in noninvasive medical monitoring, announced that the U.S. Food and Drug Administration (FDA) has cleared the Nonin Model 3230 Bluetooth Smart finger pulse oximeter for use in the United States.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now